Walgreen's (NYSE: WAG) Top Line Rises 3.1% on Strength in Prescription SalesWalgreen Co. (NYSE:WAG) reported fiscal Q2 EPS of $0.68, missing consensus estimates of $0.71.
Sales in the quarter rose 3.1% to $16.9 billion, but came in short of consensus estimates of $17.1 billion.
Walgreen Co.'s prescription revenue increased 3.2 percent as more customers filled 90-day prescriptions. Prescription sales rose just under 1 percent at stores open at least a year.
"During the quarter we continued to make progress in executing our key strategies for growth," said Walgreens President and CEO Greg Wasson. "We generated significant cash flow, despite the impact of a sluggish economy and lower-than-anticipated sales of flu-related products."